Amgen released the results of Phase 2 clinical trials for Denosumab (previously referred to as AMG 162), showing that the RANK Ligand inhibitor significantly increased bone mineral density (BMD) in the total hip, lumbar spine, distal 1/3 radius and total body. Results are published in the recent issue of the New England Journal of Medicine.

"These exciting data suggest that denosumab, when administered in twice-yearly injections, may show promise in the treatment of osteoporosis," said Michael McClung, MD, FACP, principal investigator of the denosumab study, Providence Portland Medical Center, and director of the Oregon Osteoporosis Center, Portland, Ore. "Continued research will further our understanding of the potential of denosumab in bone loss management."

Read more about Denosumab, the study design and osteoporosis from Amgen's press release.